https://www.gov.uk/government/publications/further-advice-on-scheduling-of-cannabis-derived-medicinal-products<\/a><\/p>Any unlicensed medicines, including cannabis-based products for medicinal use, will be supplied under long-standing arrangements for the supply of what are known, in healthcare settings, as \u2018specials\u2019. This process is underpinned by the Human Medicines Act and, outside of clinical trials, only allows these unlicensed medicines to be prescribed where there is an unmet clinical need. This restriction is in place because unlicensed medicines have not been through the same quality, safety and efficacy tests as licenced medicines.<\/p>"}
, "answeringMember" : {"_about" : "http://data.parliament.uk/members/1561", "label" : {"_value" : "Biography information for Mr Nick Hurd"}
}
, "answeringMemberConstituency" : {"_value" : "Ruislip, Northwood and Pinner"}
, "answeringMemberPrinted" : {"_value" : "Mr Nick Hurd"}
, "dateOfAnswer" : {"_value" : "2018-11-12", "_datatype" : "dateTime"}
, "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"}
, "questionFirstAnswered" : [{"_value" : "2018-11-12T17:05:51.537Z", "_datatype" : "dateTime"}
]}
, "answeringDeptId" : {"_value" : "1"}
, "answeringDeptShortName" : {"_value" : "Home Office"}
, "answeringDeptSortName" : {"_value" : "Home Office"}
, "date" : {"_value" : "2018-11-06", "_datatype" : "dateTime"}
, "hansardHeading" : {"_value" : "Cannabis: Medical Treatments"}
, "houseId" : {"_value" : "1"}
, "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"}
}
], "questionText" : "To ask the Secretary of State for the Home Department, if he will publish the advice used to inform his Department on the requirements that (a) the decision to prescribe medicinal cannabis products must be made by a specialist doctor and (b) medicinal cannabis products may only be prescribed when the patient has an unmet special clinical need that cannot be met by other treatments.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"}
, "tablingMember" : {"_about" : "http://data.parliament.uk/members/1439", "label" : {"_value" : "Biography information for Norman Lamb"}
}
, "tablingMemberConstituency" : {"_value" : "North Norfolk"}
, "tablingMemberPrinted" : [{"_value" : "Norman Lamb"}
], "uin" : "188750"}
, {"_about" : "http://data.parliament.uk/resources/1002107", "AnsweringBody" : [{"_value" : "Home Office"}
], "answer" : {"_about" : "http://data.parliament.uk/resources/1002107/answer", "answerText" : {"_value" : "
The Home Office leads the Government\u2019s policy and legislation on the misuse of drugs, including on the scheduling of substances controlled under the Misuse of Drugs Act 1971 and associated legislation. The Department of Health and Social Care has responsibility for the safe management and use of medicines in healthcare.<\/p>"}
, "answeringMember" : {"_about" : "http://data.parliament.uk/members/1561", "label" : {"_value" : "Biography information for Mr Nick Hurd"}
}
, "answeringMemberConstituency" : {"_value" : "Ruislip, Northwood and Pinner"}
, "answeringMemberPrinted" : {"_value" : "Mr Nick Hurd"}
, "dateOfAnswer" : {"_value" : "2018-11-15", "_datatype" : "dateTime"}
, "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"}
, "questionFirstAnswered" : [{"_value" : "2018-11-15T17:58:05.597Z", "_datatype" : "dateTime"}
]}
, "answeringDeptId" : {"_value" : "1"}
, "answeringDeptShortName" : {"_value" : "Home Office"}
, "answeringDeptSortName" : {"_value" : "Home Office"}
, "date" : {"_value" : "2018-11-05", "_datatype" : "dateTime"}
, "hansardHeading" : {"_value" : "Cannabis: Medical Treatments"}
, "houseId" : {"_value" : "1"}
, "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"}
}
], "questionText" : "To ask the Secretary of State for the Home Department, whether his Department remains the ministerial lead for the medicinal use of cannabis-based products.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"}
, "tablingMember" : {"_about" : "http://data.parliament.uk/members/4465", "label" : {"_value" : "Biography information for Ronnie Cowan"}
}
, "tablingMemberConstituency" : {"_value" : "Inverclyde"}
, "tablingMemberPrinted" : [{"_value" : "Ronnie Cowan"}
], "uin" : "188186"}
, {"_about" : "http://data.parliament.uk/resources/990352", "AnsweringBody" : [{"_value" : "Department of Health and Social Care"}
], "answer" : {"_about" : "http://data.parliament.uk/resources/990352/answer", "answerText" : {"_value" : "
NHS England expects that cannabis-based products for medicinal use should only be prescribed for indications where there is clear evidence of benefit, and in patients where there is a clinical need which cannot be met by a licensed medicine and, where established treatment options have been exhausted.<\/p>
<\/p>
The decision to prescribe these unlicensed medicines must be made by a specialist doctor \u2013 not a general practitioner. These doctors focus on one field of medicine such as neurology or paediatrics and are listed on the General Medical Council\u2019s specialist register. They must make decisions on prescribing cannabis-based products for medicinal use on a case by case basis, and only when the patient has an unmet special clinical need that cannot be met by licensed products. In addition, a specialist on the General Medical Council Register should only prescribe within their own area of practice, and the decision to prescribe should be agreed by the multidisciplinary team.<\/p>
<\/p>
NHS England, the British Paediatric Neurology Association and the Royal College of Physicians will provide clinical advice to doctors ahead of the law change. The National Institute for Health and Care Excellence has been commissioned to develop more detailed guidelines for clinicians in the longer term.<\/p>"}
, "answeringMember" : {"_about" : "http://data.parliament.uk/members/4067", "label" : {"_value" : "Biography information for Steve Brine"}
}
, "answeringMemberConstituency" : {"_value" : "Winchester"}
, "answeringMemberPrinted" : {"_value" : "Steve Brine"}
, "dateOfAnswer" : {"_value" : "2018-10-23", "_datatype" : "dateTime"}
, "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"}
, "questionFirstAnswered" : [{"_value" : "2018-10-23T16:43:24.827Z", "_datatype" : "dateTime"}
]}
, "answeringDeptId" : {"_value" : "17"}
, "answeringDeptShortName" : {"_value" : "Health and Social Care"}
, "answeringDeptSortName" : {"_value" : "Health and Social Care"}
, "date" : {"_value" : "2018-10-18", "_datatype" : "dateTime"}
, "hansardHeading" : {"_value" : "Cannabis: Medical Treatments"}
, "houseId" : {"_value" : "1"}
, "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"}
}
], "questionText" : "To ask the Secretary of State for Health and Social Care, if he will take steps to allow patients to have access to NHS doctors willing to prescribe cannabis-based medicine in cases where their NHS doctor is unwilling to do so.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"}
, "tablingMember" : {"_about" : "http://data.parliament.uk/members/1400", "label" : {"_value" : "Biography information for Kevin Brennan"}
}
, "tablingMemberConstituency" : {"_value" : "Cardiff West"}
, "tablingMemberPrinted" : [{"_value" : "Kevin Brennan"}
], "uin" : "181179"}
, {"_about" : "http://data.parliament.uk/resources/988887", "AnsweringBody" : [{"_value" : "Home Office"}
], "answer" : {"_about" : "http://data.parliament.uk/resources/988887/answer", "answerText" : {"_value" : "
From 1 November, certain cannabis-based products for medicinal use, that meet conditions related to the quality of their manufacture and supply routes, can be prescribed by doctors on the specialist register of the General Medical Council (GMC). GPs will not be able to prescribe cannabis-based medicinal products for their patients.<\/p>
There is no requirement for specialist doctors to notify the police or the Home Office when issuing prescription for these products. Controlled Drug Accountable Officers have a statutory responsibility to secure the safe management and use of controlled drugs. This includes a duty to monitor the prescribing, supply and administration (if applicable) of all controlled drugs and liaise with the police to investigate suspected diversion.<\/p>"}
, "answeringMember" : {"_about" : "http://data.parliament.uk/members/1561", "label" : {"_value" : "Biography information for Mr Nick Hurd"}
}
, "answeringMemberConstituency" : {"_value" : "Ruislip, Northwood and Pinner"}
, "answeringMemberPrinted" : {"_value" : "Mr Nick Hurd"}
, "dateOfAnswer" : {"_value" : "2018-10-24", "_datatype" : "dateTime"}
, "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"}
, "questionFirstAnswered" : [{"_value" : "2018-10-24T15:40:57.027Z", "_datatype" : "dateTime"}
]}
, "answeringDeptId" : {"_value" : "1"}
, "answeringDeptShortName" : {"_value" : "Home Office"}
, "answeringDeptSortName" : {"_value" : "Home Office"}
, "date" : {"_value" : "2018-10-16", "_datatype" : "dateTime"}
, "hansardHeading" : {"_value" : "Cannabis: Medical Treatments"}
, "houseId" : {"_value" : "1"}
, "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"}
}
], "questionText" : "To ask the Secretary of State for the Home Department, whether GPs will be required to notify (a) the police and (b) the Home Office when making prescriptions for medicinal cannabis.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"}
, "tablingMember" : {"_about" : "http://data.parliament.uk/members/4491", "label" : {"_value" : "Biography information for Vicky Foxcroft"}
}
, "tablingMemberConstituency" : {"_value" : "Lewisham, Deptford"}
, "tablingMemberPrinted" : [{"_value" : "Vicky Foxcroft"}
], "uin" : "180264"}
, {"_about" : "http://data.parliament.uk/resources/988889", "AnsweringBody" : [{"_value" : "Department of Health and Social Care"}
], "answer" : {"_about" : "http://data.parliament.uk/resources/988889/answer", "answerText" : {"_value" : "
Subject to Parliamentary approval, from 1 November doctors on the General Medical Council\u2019s specialist register can make the decision to prescribe cannabis-based products for medicinal use where deemed clinically appropriate and in the best interests of patients. Prescribers will need to follow local governance procedures for prescribing unlicensed medicines.<\/p>
<\/p>
The regulations do not limit the types of conditions that can be considered for treatment and will only be able to be supplied under the prescription or direction of a specialist doctor.<\/p>
<\/p>"}
, "answeringMember" : {"_about" : "http://data.parliament.uk/members/4067", "label" : {"_value" : "Biography information for Steve Brine"}
}
, "answeringMemberConstituency" : {"_value" : "Winchester"}
, "answeringMemberPrinted" : {"_value" : "Steve Brine"}
, "dateOfAnswer" : {"_value" : "2018-10-24", "_datatype" : "dateTime"}
, "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"}
, "questionFirstAnswered" : [{"_value" : "2018-10-24T16:57:55.353Z", "_datatype" : "dateTime"}
]}
, "answeringDeptId" : {"_value" : "17"}
, "answeringDeptShortName" : {"_value" : "Health and Social Care"}
, "answeringDeptSortName" : {"_value" : "Health and Social Care"}
, "date" : {"_value" : "2018-10-16", "_datatype" : "dateTime"}
, "hansardHeading" : {"_value" : "Cannabis: Medical Treatments"}
, "houseId" : {"_value" : "1"}
, "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"}
}
], "questionText" : "To ask the Secretary of State for Health and Social Care, whether all patients with health conditions previously determined by the Medicines and Healthcare products Regulatory Agency to benefit from the use of cannabis will automatically qualify for prescriptions for medicinal cannabis.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"}
, "tablingMember" : {"_about" : "http://data.parliament.uk/members/4491", "label" : {"_value" : "Biography information for Vicky Foxcroft"}
}
, "tablingMemberConstituency" : {"_value" : "Lewisham, Deptford"}
, "tablingMemberPrinted" : [{"_value" : "Vicky Foxcroft"}
], "uin" : "180265"}
, {"_about" : "http://data.parliament.uk/resources/972291", "AnsweringBody" : [{"_value" : "Department of Health and Social Care"}
], "answer" : {"_about" : "http://data.parliament.uk/resources/972291/answer", "answerText" : {"_value" : "
The Secretary of State for Health and Social Care has committed to his officials working closely with the Home Office on legalising the use of cannabis-based medicines, including cannabis-oil. There has not been a meeting between the Secretary of State and the Home Secretary on the potential effect of legalising cannabis-oil medicines on the availability of cannabis as a gateway drug for social use.<\/p>
<\/p>
An impact assessment is being prepared alongside proposals to consider wider impacts of this policy. There are known harms associated with cannabis use and cannabis remains a controlled drug. The Government has no plans to legalise it for recreational use. As with other medicines in Schedule 2 to the Misuse of Drugs Regulations 2001 (such as morphine and fentanyl), it will continue to be an offence contrary to the Misuse of Drugs Act 1971 to possess a cannabis based medicine without prescription or lawful authority.<\/p>"}
, "answeringMember" : {"_about" : "http://data.parliament.uk/members/4067", "label" : {"_value" : "Biography information for Steve Brine"}
}
, "answeringMemberConstituency" : {"_value" : "Winchester"}
, "answeringMemberPrinted" : {"_value" : "Steve Brine"}
, "dateOfAnswer" : {"_value" : "2018-10-09", "_datatype" : "dateTime"}
, "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"}
, "questionFirstAnswered" : [{"_value" : "2018-10-09T16:51:24.117Z", "_datatype" : "dateTime"}
]}
, "answeringDeptId" : {"_value" : "17"}
, "answeringDeptShortName" : {"_value" : "Health and Social Care"}
, "answeringDeptSortName" : {"_value" : "Health and Social Care"}
, "date" : {"_value" : "2018-09-12", "_datatype" : "dateTime"}
, "hansardHeading" : {"_value" : "Cannabis: Medical Treatments"}
, "houseId" : {"_value" : "1"}
, "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"}
}
], "questionText" : "To ask the Secretary of State for Health and Social Care, what discussions he has had with the Home Secretary on the potential effect of legalising cannabis-oil medicines on the availability of cannabis as a gateway drug for social use.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"}
, "tablingMember" : {"_about" : "http://data.parliament.uk/members/308", "label" : {"_value" : "Biography information for Mr Jim Cunningham"}
}
, "tablingMemberConstituency" : {"_value" : "Coventry South"}
, "tablingMemberPrinted" : [{"_value" : "Mr Jim Cunningham"}
], "uin" : "173953"}
, {"_about" : "http://data.parliament.uk/resources/971604", "AnsweringBody" : [{"_value" : "Home Office"}
], "answer" : {"_about" : "http://data.parliament.uk/resources/971604/answer", "answerText" : {"_value" : "
We do not hold data to assess whether there is a correlation between the sale of natural cannabis oil and the number of thefts on the high street.<\/p>
A CBD, or cannabidiol product, in its pure form is not controlled under the Misuse of Drugs Act 1971. However, a CBD product, which contains any trace of the psychoactive compounds that are found in cannabis, such as THC, is considered to be a controlled substance under the Misuse of Drugs Act 1971 and therefore unlawful to possess and supply unless it fits the criteria for an \u2018exempt product\u2019 under the Misuse of Drugs Regulations 2001.<\/p>
Enforcement of illegal sales of drugs is an operational matter for the police but we expect them to enforce the law.<\/p>"}
, "answeringMember" : {"_about" : "http://data.parliament.uk/members/1561", "label" : {"_value" : "Biography information for Mr Nick Hurd"}
}
, "answeringMemberConstituency" : {"_value" : "Ruislip, Northwood and Pinner"}
, "answeringMemberPrinted" : {"_value" : "Mr Nick Hurd"}
, "dateOfAnswer" : {"_value" : "2018-10-09", "_datatype" : "dateTime"}
, "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"}
, "questionFirstAnswered" : [{"_value" : "2018-10-09T15:30:25.53Z", "_datatype" : "dateTime"}
]}
, "answeringDeptId" : {"_value" : "1"}
, "answeringDeptShortName" : {"_value" : "Home Office"}
, "answeringDeptSortName" : {"_value" : "Home Office"}
, "date" : {"_value" : "2018-09-11", "_datatype" : "dateTime"}
, "hansardHeading" : {"_value" : "Cannabis: Medical Treatments"}
, "houseId" : {"_value" : "1"}
, "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"}
}
], "questionText" : "To ask the Secretary of State for the Home Department, what assessment he has made of whether there is a correlation between the unrestricted sale of natural cannabis oil in health stores and the number of thefts on the high street; and if he will make a statement.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"}
, "tablingMember" : {"_about" : "http://data.parliament.uk/members/308", "label" : {"_value" : "Biography information for Mr Jim Cunningham"}
}
, "tablingMemberConstituency" : {"_value" : "Coventry South"}
, "tablingMemberPrinted" : [{"_value" : "Mr Jim Cunningham"}
], "uin" : "173514"}
, {"_about" : "http://data.parliament.uk/resources/968170", "AnsweringBody" : [{"_value" : "Home Office"}
], "answer" : {"_about" : "http://data.parliament.uk/resources/968170/answer", "answerText" : {"_value" : "
Government has announced an aim to reschedule cannabis in the autumn. This will enable specialist clinicians to legally prescribe cannabis-derived medicinal products to patients with an exceptional clinical need. In the interim the Expert Panel has been established to review applications from specialist clinicians who wish to prescribe specified cannabis derived medicinal products. For each application, the panel are looking for a specialist clinician to meet their criteria and show that there are exceptional clinical circumstances before recommending that a licence should be issued.<\/p>
As of 06 September 2018 there have been forty four inquiries to the expert panel mailbox from members of the public, patients, doctors and press. The number of applications to the panel has been small there is a significant risk that even aggregate information disclosed about applications could be linked to personal details (made available through media reporting). Given that the Home Office has a duty to protect these individuals the actual number of applications cannot be disclosed.<\/p>"}
, "answeringMember" : {"_about" : "http://data.parliament.uk/members/1561", "label" : {"_value" : "Biography information for Mr Nick Hurd"}
}
, "answeringMemberConstituency" : {"_value" : "Ruislip, Northwood and Pinner"}
, "answeringMemberPrinted" : {"_value" : "Mr Nick Hurd"}
, "dateOfAnswer" : {"_value" : "2018-09-10", "_datatype" : "dateTime"}
, "groupedQuestionUIN" : {"_value" : "170719"}
, "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"}
, "questionFirstAnswered" : [{"_value" : "2018-09-10T16:02:09.443Z", "_datatype" : "dateTime"}
]}
, "answeringDeptId" : {"_value" : "1"}
, "answeringDeptShortName" : {"_value" : "Home Office"}
, "answeringDeptSortName" : {"_value" : "Home Office"}
, "date" : {"_value" : "2018-09-05", "_datatype" : "dateTime"}
, "hansardHeading" : {"_value" : "Cannabis: Medical Treatments"}
, "houseId" : {"_value" : "1"}
, "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"}
}
], "questionText" : "To ask the Secretary of State for the Home Department, how many licence applications for medicinal cannabis have been received by the expert panel; and what the status is of those applications.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"}
, "tablingMember" : {"_about" : "http://data.parliament.uk/members/1439", "label" : {"_value" : "Biography information for Norman Lamb"}
}
, "tablingMemberConstituency" : {"_value" : "North Norfolk"}
, "tablingMemberPrinted" : [{"_value" : "Norman Lamb"}
], "uin" : "170718"}
, {"_about" : "http://data.parliament.uk/resources/968171", "AnsweringBody" : [{"_value" : "Home Office"}
], "answer" : {"_about" : "http://data.parliament.uk/resources/968171/answer", "answerText" : {"_value" : "
Government has announced an aim to reschedule cannabis in the autumn. This will enable specialist clinicians to legally prescribe cannabis-derived medicinal products to patients with an exceptional clinical need. In the interim the Expert Panel has been established to review applications from specialist clinicians who wish to prescribe specified cannabis derived medicinal products. For each application, the panel are looking for a specialist clinician to meet their criteria and show that there are exceptional clinical circumstances before recommending that a licence should be issued.<\/p>
As of 06 September 2018 there have been forty four inquiries to the expert panel mailbox from members of the public, patients, doctors and press. The number of applications to the panel has been small there is a significant risk that even aggregate information disclosed about applications could be linked to personal details (made available through media reporting). Given that the Home Office has a duty to protect these individuals the actual number of applications cannot be disclosed.<\/p>"}
, "answeringMember" : {"_about" : "http://data.parliament.uk/members/1561", "label" : {"_value" : "Biography information for Mr Nick Hurd"}
}
, "answeringMemberConstituency" : {"_value" : "Ruislip, Northwood and Pinner"}
, "answeringMemberPrinted" : {"_value" : "Mr Nick Hurd"}
, "dateOfAnswer" : {"_value" : "2018-09-10", "_datatype" : "dateTime"}
, "groupedQuestionUIN" : {"_value" : "170718"}
, "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"}
, "questionFirstAnswered" : [{"_value" : "2018-09-10T16:02:09.507Z", "_datatype" : "dateTime"}
]}
, "answeringDeptId" : {"_value" : "1"}
, "answeringDeptShortName" : {"_value" : "Home Office"}
, "answeringDeptSortName" : {"_value" : "Home Office"}
, "date" : {"_value" : "2018-09-05", "_datatype" : "dateTime"}
, "hansardHeading" : {"_value" : "Cannabis: Medical Treatments"}
, "houseId" : {"_value" : "1"}
, "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"}
}
], "questionText" : "To ask the Secretary of State for the Home Department, how many inquiries the medicinal cannabis licensing panel has received from potential applicants.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"}
, "tablingMember" : {"_about" : "http://data.parliament.uk/members/1439", "label" : {"_value" : "Biography information for Norman Lamb"}
}
, "tablingMemberConstituency" : {"_value" : "North Norfolk"}
, "tablingMemberPrinted" : [{"_value" : "Norman Lamb"}
], "uin" : "170719"}
], "itemsPerPage" : 10, "next" : "http://eldaddp.azurewebsites.net/answeredquestions.text?_page=1&houseId=1&hansardHeading=Cannabis%3A+Medical+Treatments&max-answer.dateOfAnswer=2018-11-15", "page" : 0, "startIndex" : 1, "totalResults" : 36, "type" : ["http://purl.org/linked-data/api/vocab#ListEndpoint", "http://purl.org/linked-data/api/vocab#Page"]}
}